Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IrelandIPO:
18 December 2012Website:
http://www.prothena.comNext earnings report:
14 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 21:34:32 GMTDividend
Analysts recommendations
Institutional Ownership
PRTA Latest News
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer.
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
Prothena (PRTA) lacks the necessary elements for a potential earnings beat in its upcoming report. Be ready with the important expectations.
Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.
- 1(current)
What type of business is Prothena?
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
What sector is Prothena in?
Prothena is in the Healthcare sector
What industry is Prothena in?
Prothena is in the Biotechnology industry
What country is Prothena from?
Prothena is headquartered in Ireland
When did Prothena go public?
Prothena initial public offering (IPO) was on 18 December 2012
What is Prothena website?
https://www.prothena.com
Is Prothena in the S&P 500?
No, Prothena is not included in the S&P 500 index
Is Prothena in the NASDAQ 100?
No, Prothena is not included in the NASDAQ 100 index
Is Prothena in the Dow Jones?
No, Prothena is not included in the Dow Jones index
When was Prothena the previous earnings report?
No data
When does Prothena earnings report?
The next expected earnings date for Prothena is 14 February 2025